Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA).
J Pharm Biomed Anal
; 88: 162-9, 2014 Jan.
Article
en En
| MEDLINE
| ID: mdl-24055700
Palabras clave
2-PMPA; 2-PMSA; 2-phosphonomethyl pentanedioic acid; 2-phosphonomethyl succinic acid; ANOVA; AUC; AULQ; Brain/plasma ratio; C(max); CE; CXP; DP; DRG; Derivatization; EP; GCP-II; Glutamate carboxypeptidase-II; HQC; LLOQ; LQC; MQC; MTBSTFA; N-acetyl-aspartyl glutamate; N-acetylated-alpha-linked acidic dipeptidase; N-tert-butyldimethysilyl-N-methyl trifluoroacetamide; NAAG; NAALADase; PSMA; Pharmacokinetics; T(max); above upper limits of quantitation; area under the concentrationtime curve; collision cell exit potential; collision energy; declustering potential; dorsal root ganglion; entrance potential; glutamate carboxypeptidase-II; high quality control; low quality control; lower limit of quantitation; maximum plasma concentration; medium quality control; one-way analysis of variance; prostate specific membrane antigen; time to C(max)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Compuestos Organofosforados
/
Plasma
/
Glutamato Carboxipeptidasa II
/
Inhibidores Enzimáticos
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
J Pharm Biomed Anal
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Reino Unido